QLT Inc. Completes Enrollment in its Natural History Study

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
QLT Inc. Completes Enrollment in its Natural History Study

VANCOUVER, British Columbia, April 22, 2016 (GLOBE NEWSWIRE) -- QLT Inc. (NASDAQ: QLTI ); (TSX: QLT ) (“QLT” or the “Company”) announced today completion of enrollment in its retrospective, uncontrolled, multicenter Natural History Study in subjects with Inherited Retinal Disease (IRD) phenotypically diagnosed with Retinitis Pigmentosa (RP) or Leber Congenital Amaurosis (LCA) due to underlying Retinal Pigment Epithelial 65 protein (RPE65) or Lecithin:Retinol Acyltransferase (LRAT) gene mutations. The objective of the retrospective, open label study is to gather data on the natural progression of the disease in subjects over time, including from childhood through to adulthood.  The study included both subjects who had previously received treatment in QLT-sponsored clinical trials with QLT’s synthetic oral retinoid product, QLT091001, as well as subjects who had not received any prior therapeutic treatment.  For subjects who had received prior treatment with QLT091001, the study included a retrospective review of subjects’ medical records prior to and after treatment with QLT091001.

“We are very pleased to have completed on schedule the collection of the data from what we believe to be the first retrospective natural history clinical study conducted specifically in RP and LCA patients due to underlying RPE65 or LRAT gene mutations,” said Geoffrey F. Cox Ph.D., QLT’s Interim Chief Executive Officer.  “We sincerely thank our participating physicians, all of whom are noted leaders in the field of Inherited Retinal Disease, along with their corresponding sites for their contributions to this study.  Although the deterioration over time of both visual field and visual acuity and various other visual functions in these patients, has, for a long time, been the assumption of treating physicians of these patients, we believe this study will provide important comparative data for the future treatment and care of these patients.  This study is also expected to provide important data to support the ongoing development program for QLT091001, including our planned future submissions for regulatory approval in Europe and the U.S.  Following our planned discussions with regulatory authorities, we look forward to publicly reporting the final results from the Natural History Study.”

Historically, it has been generally accepted that subjects born with  IRD  due to RPE65 or LRAT  gene mutations would be expected to demonstrate an overall decline in visual field and visual acuity, but at varying rates and over varying periods of time (years).  In addition, these patients may also demonstrate increasing retinal atrophy as the disease progresses.  The intention of this study was to collect data from these patients retrospectively, but under a formal protocol, thereby providing an opportunity to better observe and understand the long term natural disease progression of untreated patients, and to provide comparative data to further assess the extent to which treatment with QLT091001 may prolong or improve visual function relative to the underlying natural disease progression in these subjects.  The study was a multi-site study intended to enroll up to 60 subjects from established IRD patient populations at 10 clinical study sites in Europe, the U.S. and Canada.  In total, 59 patients were enrolled in the study, 25 of whom had participated in previous clinical studies with QLT091001, and 34 of whom were treatment naive.  Data was collected from patient records for a variety of visual outcome measures, with particular reference to changes in visual field and visual acuity for individual subjects over multiple years, and in some cases, decades, often starting in childhood.

The Company has completed its preliminary analysis and believes that the data suggests that these patients, without other interventions, demonstrate a continuing decline in visual field and eventually visual acuity over time.

The Company intends to present the results for discussion with selected national European Agencies and later with the U.S. FDA.  As a follow-up to previous meetings held with European regulatory authorities in the first quarter of 2015 to discuss the potential for conditional approval of QLT091001 on the basis of existing clinical data, a meeting with selected national European Agencies is scheduled to take place during the second quarter of 2016.  The purpose of the meeting is to present the results of the Natural History Study and discuss whether the results may support a potential filing of a marketing authorization application (MAA) to the EMA for conditional approval in the second half of this year.

In addition, the Company is working towards initiating a pivotal, Phase III multi-center, placebo-controlled, double-masked clinical study for this indication potentially in the third quarter of 2016.  The objective of this study will be to further evaluate the efficacy (with particular reference to changes in visual field and visual acuity) and safety of QLT091001,  with a goal of supporting future application for full approval of QLT091001 for this indication to the EMA and the U.S. FDA.  The pivotal trial is expected to enroll 48 patients at approximately 12 sites in the EU, U.S. and Canada.

About Synthetic Retinoid Drugs

Inherited retinal diseases in the eye such as Leber Congenital Amaurosis (LCA) and Retinitis Pigmentosa (RP) arise from gene mutations of enzymes or proteins required in the biochemistry of vision. QLT091001 is a replacement for 11-cis-retinal, which is an essential component of the retinoid-rhodopsin cycle and visual function, and is under investigation for the treatment of Inherited Retinal Disease (IRD) in subjects phenotypically diagnosed with Retinitis Pigmentosa (RP) or Leber Congenital Amaurosis (LCA) due to underlying gene mutations in RPE65 or LRAT. QLT091001 has received orphan drug designations for the treatment of LCA and RP (all mutations) by the European Medicines Agency, and for the treatment of RP (all mutations) and LCA (due to inherited mutations in the LRAT and RPE65 genes) by the U.S. Food and Drug Administration (FDA).  The drug has also been granted two Fast Track designations by the FDA for the treatment of the LRAT and RPE65 genetic mutations in both LCA and autosomal recessive RP.

About Leber Congenital Amaurosis (LCA) Due to RPE65 and LRAT Mutations

LCA is an inherited degenerative retinal disease characterized by abnormalities such as roving eye movements and sensitivity to light, and manifesting in severe vision loss from birth. Both rod and cone photoreceptors are affected in LCA. Eye examinations of infants with LCA reveal normal appearing retinas. However, a low level of retinal activity, measured by electroretinography, indicates very little visual function. According to current epidemiological estimates, LCA affects approximately one in 81,000 newborns worldwide, of which approximately 10% carry the inherited deficiencies of either RPE65 or LRAT.

About Retinitis Pigmentosa (RP) Due to RPE65 and LRAT Mutations

RP is a set of hereditary retinal diseases demonstrating clinical features similar to LCA. RP is also characterized by degeneration of rod and cone photoreceptors, but it presents with a more variable loss of vision in late childhood to adulthood. Deficits in dark adaptation and peripheral vision are particular hallmarks of RP. RP is currently estimated to affect at least 300,000 individuals worldwide, of which approximately 20%-30% are autosomal recessive (arRP). It is currently estimated that less than 3% of autosomal recessive RP patients carry the inherited deficiencies of either RPE65 or LRAT.

About QLT

QLT is a biotechnology company dedicated to the development and commercialization of innovative ocular products that address the unmet medical needs of patients and clinicians worldwide. We are focused on developing our synthetic retinoid program for the treatment of certain inherited retinal diseases.

QLT’s head office is based in Vancouver, Canada and the Company is publicly traded on NASDAQ Stock Market (symbol: QLTI) and the Toronto Stock Exchange (symbol: QLT). For more information about the Company’s products and developments, please visit our web site at www.qltinc.com .

Certain statements in this press release constitute “forward-looking statements” of QLT within the meaning of the Private Securities Litigation Reform Act of 1995 and constitute “forward-looking information” within the meaning of applicable Canadian securities laws.  Forward-looking statements include, but are not limited to: our statements concerning the potential efficacy, safety and market potential for QLT091001; statements concerning the potential results and utility of the Natural History Study, and the expected timing to complete the final data analysis and potential discussions with the regulatory authorities; statements concerning our ability to and anticipated timing to make submissions to the regulatory authorities concerning QLT091001, including potentially for conditional approval with the EMA and potentially for full approval with the EMA and FDA; statements concerning our plans to and expected timing to commence a pivotal trial in QLT091001; and statements which contain language such as: “assuming,” “prospects,” “goal,” “future” “projects,” “potential,” “could,” “believes,” “expects”; “hopes” and “outlook.” Forward-looking statements are predictions only which involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from those expressed in such statements. Many such risks, uncertainties and other factors are taken into account as part of our assumptions underlying these forward-looking statements and include, among others, the following risks, uncertainties and other factors: the effect that QLT’s announcements and actions will have on the market price of our securities; QLT’s development plans, timing and results of the clinical development of our synthetic retinoid program are uncertain; the risk that it may take longer and cost more than anticipated to complete data analyses, complete preparatory work, meet with regulators and commence trials (including a pivotal trial) for numerous reasons both within and outside of our control; assumptions related to the associated costs of our synthetic retinoid program may prove incorrect; the risk that outcomes for our clinical trials may not be favorable or may be less favorable than interim/preliminary results disclosed and/or previous trials; the possibility that interpretations of data produced by one or more of our clinical trials will vary, including by the regulatory authorities;  the timing, expense and uncertainty associated with the regulatory approval process for products to advance through development stages; risks and uncertainties associated with the safety and effectiveness of our synthetic retinoid program; risks and uncertainties related to the scope, validity, and enforceability of our intellectual property rights and the impact of patents and other intellectual property of third parties; the Company’s future operating results, which are uncertain and likely to fluctuate; currency fluctuations; and general economic conditions and other factors described in detail in QLT’s Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and other filings with the U.S. Securities and Exchange Commission and Canadian securities regulatory authorities. Forward-looking statements are based on the current expectations of QLT and QLT does not assume any obligation to update such information to reflect later events or developments except as required by law.

QLT Inc. Contacts: Investor Relations Andrea Rabney or David Pitts Argot Partners 212-600-1902 andrea@argotpartners.com david@argotpartners.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

AV Access iDock B12 Chases the Growing Two-PC Desk Boom

Updated Category News Views 149

Cable spaghetti has become an oddly durable tax on anyone running a work laptop beside a gaming tower, and AV Access is taking a proper swing at it with the iDock B12. This is not some mystical new category; it is a KVM switch and docking station mashed together for a desk that has to serve two masters. Still, the company has aimed at the parts that usually get sacrificed...

Continue Reading
COFE+ Barista Test Puts Robotic Coffee on the Clock

Updated Category News Views 66

A swan latte taking 18 seconds less is not nothing, even if it is hardly a verdict on the future of coffee. COFE+, the seventh-generation robotic barista from Shanghai Hi-Dolphin Robot Technology, beat an award-winning human barista across five drinks at a live November 14 competition in Yiwu. That is a clean, visible demonstration of what machines are increasingly built...

Continue Reading
YPTC’s Florida Office Bets on Nonprofit Finance Needs

Updated Category News Views 36

A Local Flag Planted After Years of Work Florida nonprofits do not need another consultant waving a glossy slide deck around; they need clean books, grant compliance, and somebody who can tell them where the cash is going before the lights start blinking red. That is the practical opening YPTC is chasing with a Jacksonville-based Florida office, its sixteenth office...

Continue Reading
North Richland Hills Bets on Its Visitor Momentum Now

Updated Category News Views 49

A crowded family attraction map is a nice problem for a Texas city to have, and North Richland Hills is trying to turn that pile of assets into a cleaner regional tourism machine. On Nov. 20, 2026, the city introduced “The Place You Never Outgrow,” its first destination-marketing campaign, built with Flat Five Marketing. This is not a stock story in the usual...

Continue Reading
Baker Tilly Breach Raises Hard Questions on Vendor Risk

Updated Category News Views 191

A Quiet Vendor Failure Can Become a Loud Problem Tax files are not ordinary customer records, and that is why this reported Baker Tilly Advisory Group breach deserves more than the usual shrug people give cyber incidents. Names and addresses are bad enough; the potential exposure of Social Security numbers and other sensitive information turns a systems failure into a...

Continue Reading
Healthcare's Prevention Puzzle Needs Better Incentives

Updated Category News Views 11

When Savings Belong to the Next Plan A patient changing insurance plans can turn prevention into nobody’s asset. That is the uncomfortable little engine inside Russell Greenfield’s recent argument: an insurer may pay today for a program that helps prevent chronic illness, only to watch the eventual savings land with another plan after the member moves on. The person...

Continue Reading
First Horizon Opens Its Charlotte Office in South End

Updated Category News Views 161

A Building Is Not a Balance Sheet Charlotte got a fresh First Horizon sign at 110 East Boulevard on Nov. 19, 2026, and that is a sensible move, not a magic trick. The bank has officially opened a corporate office in the city’s South End neighborhood, positioning the team to develop client relationships across the Charlotte area and broaden its regional footprint. That...

Continue Reading
Huawei's Financial AI Push Targets Scale, Not Demos

Updated Category News Views 79

Banking AI has reached the point where a clever chatbot barely moves the needle. Huawei's message at Singapore FinTech Festival 2026 was aimed squarely at that harder, more expensive problem: turning AI from a scattered pilot project into machinery a financial institution can operate, govern, repeat, and improve without handing over its crown jewels. Ownership Is the...

Continue Reading
Mason Adds Nonprofit Expertise to Institutional Bench

Updated Category News Views 18

Endowment committees rarely need more noise; they need somebody who has actually sat through the uncomfortable votes. Mason Investment Advisory Services has hired Rebecca “Becky” Farnsworth, CFA, as a senior investment consultant, and this looks like a practical addition rather than the usual chest-thumping personnel announcement. Her stated focus will be...

Continue Reading
Travel Awards Spotlight Luxury Hospitality's Reach

Updated Category News Views 70

Hong Kong’s awards roll call reads less like a scorecard than a map of where premium travel wants its money and attention to go next. The 2026 World’s Travel & Hotel Awards, released November 20, cast a very wide net: heritage palaces, city hotels, beach retreats, airlines, cruise operators, tourism boards, restaurants, serviced apartments and a fair number of...

Continue Reading

Top 5 Most Recently Viewed Articles

Growth Forecast for Vehicle Leasing Market in Europe by 2029

Updated Category News Views 185

Understanding the European Vehicle Leasing Market The vehicle leasing market in Europe is poised for substantial growth, with projections indicating an increase by USD 10.1 billion from 2025 to 2029. This market expansion is largely fueled by cost-effective strategies for acquiring vehicles, combined with a growing preference for leasing over purchasing vehicles outright....

Continue Reading
Creative Realities Welcomes Tamra Koshewa as CFO

Updated Category News Views 213

Creative Realities Strengthens Leadership with New CFO Creative Realities, Inc. (NASDAQ: CREX) has announced the appointment of Tamra Koshewa as its Chief Financial Officer, set to take on her new role in the upcoming month. With a rich history spanning three decades in the finance sector, Koshewa brings a wealth of knowledge and expertise that will be vital to the...

Continue Reading
Explore the Unique Ecosystem of Angry Pepe Fork and its Future

Updated Category News Views 210

A New Era for Meme Coins with Angry Pepe Fork In the fast-paced and ever-evolving world of cryptocurrencies, Angry Pepe Fork ($APORK) is making waves by offering a fresh and exciting approach to meme coins. As the market becomes more crowded, projects like Angry Pepe Fork are not just following trends; they're setting them. With the official announcement of their roadmap...

Continue Reading
Understanding Dow's Current Bearish Options Activities

Updated Category News Views 231

Understanding Dow's Current Bearish Options Activities In recent trading sessions, investors have taken a notably bearish stance on Dow (DOW). This growing trend among deep-pocketed investors indicates shifts that market players should heed. The unusual options activity surrounding Dow highlights a significant movement worth analyzing. Although the identities of these...

Continue Reading
Unlocking Investment Growth: The TRV Success Story Revealed

Updated Category News Views 120

Understanding Growth: A Look at Travelers Companies Travelers Companies has demonstrated impressive performance in the stock market, reflecting a consistent investment strategy that appeals to many investors. Over the last five years, the company has remarkably exceeded market expectations, returning an average of 17.18% annually, showcasing its potential for substantial...

Continue Reading